Clinical Trials Logo
  1. Home
  2. Other
  3. NCT02035683

PET/CT Scan as a Tool to Rationalize the Treatment of of Advanced NSCLC Patients Undergoing First Chemotherapy — PETRA  

Non-small Cell Lung Cancer Metastatic Clinical Trial

Official title:
Study of the Role of Metabolic Response Measured by PET/CT Scan After 1 Cycle of Chemotherapy in Patients With Advanced Non Small Cell Lung Cancer (NSCLC)

Clinical Trial Summary

The purpose of this study is to test whether an early metabolic response, measured by PET/CT scan after the first cycle of chemotherapy, is able to predict which patients with advanced NSCLC have a better prognosis.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02035683
Study type Interventional
Source National Cancer Institute, Naples
Contact
Status Active, not recruiting
Phase N/A
Start date October 2013
Completion date December 2024
View Details
See also
  Status Clinical Trial Phase
Completed NCT01523340 - A Prospective Observational Study Evaluating c-MET Expression and EGFR Gene Mutation Correlation With Erlotinib Response
Recruiting NCT03956641 - Evolution of the Physical Condition in Treated Cancer Patients N/A
Completed NCT01848613 - Study of Patient Preference for Oral or Intravenous Vinorelbine in the Treatment of Advanced NSCLC Phase 4
Suspended NCT01320501 - Experience of Erlotinib in Patients With Advanced Non-Small Cell Lung Cancer Phase 4
Terminated NCT01471964 - Study to Assess Safety and Tolerability of MLN8237, In Combination With Erlotinib to Treat Non-Small Cell Lung Cancer Phase 1/Phase 2
Recruiting NCT06127940 - K-SAB Trial - Sotorasib Followed by SBRT to 1-3 Lesions in Advanced NSCLC With KRASG12C Mutation Phase 1
Terminated NCT04069936 - Marrow Infiltrating Lymphocytes - Non-Small Cell Lung Cancer (MILs™ - NSCLC) Alone or in Combination With Nivolumab With or Without Tadalafil in Locally Advanced and Unresectable or Metastatic NSCLC Phase 2
Terminated NCT03445000 - ALEctinib for the Treatment of Pretreated RET-rearranged Advanced Non-small Cell Lung Cancer Phase 2
Terminated NCT03386929 - Survival Prolongation by Rationale Innovative Genomics Phase 1/Phase 2
Recruiting NCT02922764 - A Study of RGX-104 in Patients With Advanced Lung & Endometrial Cancer Phase 1
Terminated NCT01574300 - Collaborative Advanced Stage Tissue Lung Cancer (CASTLE) Network
Active, not recruiting NCT04646824 - Almonertinib With Chemotherapy in mEGFR NSCLC Phase 2
Completed NCT01966003 - Efficacy and Safety Study of ABP 215 Compared With Bevacizumab in Patients With Advanced Non-Small Cell Lung Cancer Phase 3
Recruiting NCT03656094 - Chemotherapy With Pembrolizumab Continuation After Progression to PD-1/L1 Inhibitors Phase 2
Terminated NCT01348126 - Study of Ganetespib (STA-9090) + Docetaxel in Advanced Non Small Cell Lung Cancer Phase 2/Phase 3
Active, not recruiting NCT03469960 - Double Immune Checkpoint Inhibitors in PD-L1-positive Stage IV Non-small Lung CancEr Phase 3
Recruiting NCT05919264 - FOG-001 in Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Completed NCT04793815 - Lung Cancer Cryo-Activation as a Novel Approach to Augment Immunotherapy Efficacy (CRYOVATE) N/A
Terminated NCT01380795 - Feasibility of the Research for Mutation of K-ras and EGFR in CTCs From Metastatic Non Small Cells Bronchial Carcinomas Early Phase 1
Completed NCT02959619 - Ensartinib in Non-small Cell Lung Cancer Patients With Positive ALK Phase 1